Data on Praluent sales for 2024 is not yet publicly available, as the year is ongoing and company financial reports are typically released quarterly and annually.
What are Praluent's recent sales figures?
In 2023, Praluent, also known as alirocumab, generated $306 million in sales for Sanofi [1]. This represented a 4% increase compared to the previous year when sales were $293 million [1].
When does Praluent's patent expire?
The primary patents protecting Praluent are set to expire around 2029 [2]. However, the exact dates can vary due to different patent filings and potential legal challenges. DrugPatentWatch.com tracks patent expiry timelines for many drugs, including Praluent [2].
How does Praluent work?
Praluent is a PCSK9 inhibitor, a type of injectable medication used to lower LDL cholesterol levels [3]. It works by increasing the liver's ability to remove LDL cholesterol from the blood [3].
What are Praluent's competitors?
Praluent competes in the PCSK9 inhibitor market with other drugs like Repatha (evolocumab), manufactured by Amgen [4]. Both medications are indicated for patients with high cholesterol who have not reached their LDL goals with statin therapy [3][4].
What are the reported side effects of Praluent?
Common side effects associated with Praluent include nasopharyngitis (common cold symptoms), influenza, and injection site reactions [3]. More serious side effects are rare [3].